Cervical Cancer Screening Remains Low Globally
Only 35% of women worldwide were screened in 2022, falling short of international health goals.
Updated on Oct. 21, 2026 in Cancer
Live Poll
Should nations prioritize increasing global access to preventive cancer screenings for all citizens?
In 2022, only 35% of women aged 30-49 globally underwent cervical cancer screening, highlighting a major gap in access. This wide variation in diagnostic testing leaves many women in low- and middle-income countries without early detection, even as more nations adopt modern HPV screening recommendations.
Why it matters
Effective screening is essential to detect and treat precancerous lesions before they progress to cancer, a step the WHO identifies as vital for global elimination of the disease. Bridging these disparities is necessary to ensure equitable access to life-saving preventive care.
A global assessment of screening across 202 countries and territories found that only 35% of women aged 30-49 received cervical cancer screening in 2022. While 92 countries have recommended HPV-based testing by 2025, wide disparities persist compared to the 80% coverage seen in Australia and New Zealand.
The players
World Health Organization
The specialized United Nations agency responsible for international public health, which aims to eliminate cervical cancer as a public health problem during this century.
The details
The WHO prioritizes HPV testing because it effectively identifies women at higher risk for developing cervical cancer compared to traditional cytology. When implemented, screening programs facilitate the identification and management of precancerous lesions. Although 20 countries had fully implemented HPV-based screening by 2022, many regions still rely on less accessible or less precise methods, contributing to the current global coverage gap.
Timeline
In 2022, global cervical cancer and HPV screening coverage was estimated.
By 2025, 92 countries recommended HPV-based screening.
The WHO set 2030 as the target year to achieve 70% screening coverage.
Health Landscape
This study provides a baseline update on the WHO cervical cancer elimination strategy. It reflects the ongoing transition from traditional screening methods to HPV-based programs across diverse international healthcare systems.
Women aged 30-49 should consult a physician to understand local screening availability and the role of HPV testing in their own preventive care. Understanding whether your region has adopted HPV-based screening is a key step in identifying appropriate testing intervals and risk assessment.
The takeaway
Early detection remains the most effective tool to prevent cervical cancer progression through timely intervention. Talk to your healthcare provider about recommended screening schedules and the benefits of HPV-based testing for your specific age group.
Further reading
For more on the current state of diagnostic testing, explore our guide on Cancer.
Live Poll
Should nations prioritize increasing global access to preventive cancer screenings for all citizens?
